| Teva Canada Ltd v Pfizer Canada Inc | |
|---|---|
 | |
| Hearing: April 18, 2012 Judgment: November 8, 2012 | |
| Full case name | Teva Canada Limited v Pfizer Canada Inc., Pfizer Inc., Pfizer Ireland Pharmaceuticals, Pfizer Research and Development Company N.V./S.A. and Minister of Health |
| Citations | 2012 SCC 60 |
| Docket No. | 33951 [1] |
| Prior history | APPEAL from Novopharm Limited v. Pfizer Canada Inc., 2010 FCA 242 (23 September 2010), affirming Pfizer Canada Inc. v. Novopharm Limited, 2009 FC 638 (18 June 2009). |
| Ruling | Appeal allowed |
| Holding | |
| The disclosure requirement in Patent Act is evaluated with respect to each invention in the patent, and not necessarily with each individual patent claim. | |
| Court membership | |
| Chief Justice: Beverley McLachlin Puisne Justices: Louis LeBel, Marie Deschamps, Morris Fish, Rosalie Abella, Marshall Rothstein, Thomas Cromwell, Michael Moldaver, Andromache Karakatsanis | |
| Reasons given | |
| Unanimous reasons by | LeBel J. |
| Fish and Karakatsanis JJ. took no part in the consideration or decision of the case. | |
Teva Canada Ltd v Pfizer Canada Inc, 2012 SCC 60 is a leading Supreme Court of Canada decision on the disclosure requirements for a patent in Canada.
- ^ SCC Case Information - Docket 33951 Supreme Court of Canada
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search